S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.19 (-0.53%)
AAPL   168.42 (-0.48%)
MSFT   287.12 (-0.71%)
META   177.42 (-0.52%)
GOOGL   118.79 (-0.76%)
AMZN   140.62 (-1.45%)
TSLA   859.86 (-2.63%)
NVDA   179.33 (-0.91%)
NIO   20.80 (+3.74%)
BABA   94.82 (+2.59%)
AMD   98.07 (-0.99%)
MU   62.26 (+1.40%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.94 (+2.33%)
F   15.82 (+2.06%)
DIS   117.83 (+4.80%)
AMC   25.40 (+7.31%)
PYPL   99.08 (+0.17%)
PFE   48.32 (-3.26%)
NFLX   242.66 (-0.59%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.19 (-0.53%)
AAPL   168.42 (-0.48%)
MSFT   287.12 (-0.71%)
META   177.42 (-0.52%)
GOOGL   118.79 (-0.76%)
AMZN   140.62 (-1.45%)
TSLA   859.86 (-2.63%)
NVDA   179.33 (-0.91%)
NIO   20.80 (+3.74%)
BABA   94.82 (+2.59%)
AMD   98.07 (-0.99%)
MU   62.26 (+1.40%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.94 (+2.33%)
F   15.82 (+2.06%)
DIS   117.83 (+4.80%)
AMC   25.40 (+7.31%)
PYPL   99.08 (+0.17%)
PFE   48.32 (-3.26%)
NFLX   242.66 (-0.59%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.19 (-0.53%)
AAPL   168.42 (-0.48%)
MSFT   287.12 (-0.71%)
META   177.42 (-0.52%)
GOOGL   118.79 (-0.76%)
AMZN   140.62 (-1.45%)
TSLA   859.86 (-2.63%)
NVDA   179.33 (-0.91%)
NIO   20.80 (+3.74%)
BABA   94.82 (+2.59%)
AMD   98.07 (-0.99%)
MU   62.26 (+1.40%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.94 (+2.33%)
F   15.82 (+2.06%)
DIS   117.83 (+4.80%)
AMC   25.40 (+7.31%)
PYPL   99.08 (+0.17%)
PFE   48.32 (-3.26%)
NFLX   242.66 (-0.59%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.19 (-0.53%)
AAPL   168.42 (-0.48%)
MSFT   287.12 (-0.71%)
META   177.42 (-0.52%)
GOOGL   118.79 (-0.76%)
AMZN   140.62 (-1.45%)
TSLA   859.86 (-2.63%)
NVDA   179.33 (-0.91%)
NIO   20.80 (+3.74%)
BABA   94.82 (+2.59%)
AMD   98.07 (-0.99%)
MU   62.26 (+1.40%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.94 (+2.33%)
F   15.82 (+2.06%)
DIS   117.83 (+4.80%)
AMC   25.40 (+7.31%)
PYPL   99.08 (+0.17%)
PFE   48.32 (-3.26%)
NFLX   242.66 (-0.59%)
NASDAQ:EXAS

Exact Sciences - EXAS Stock Forecast, Price & News

$42.36
-2.77 (-6.14%)
(As of 08/11/2022 03:59 PM ET)
Add
Compare
Today's Range
$42.08
$46.08
50-Day Range
$35.61
$51.22
52-Week Range
$35.34
$108.99
Volume
197,352 shs
Average Volume
1.88 million shs
Market Capitalization
$7.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.00

Exact Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
67.5% Upside
$71.00 Price Target
Short Interest
Healthy
5.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.06mentions of Exact Sciences in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$251,872 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.21) to ($3.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

61st out of 1,112 stocks

Medical Laboratories Industry

2nd out of 27 stocks

EXAS stock logo

About Exact Sciences (NASDAQ:EXAS) Stock

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Analyst Upgrades and Downgrades

EXAS has been the subject of several research reports. Cowen cut their price objective on Exact Sciences from $83.00 to $67.00 and set an "outperform" rating for the company in a research report on Wednesday, August 3rd. Citigroup lowered their target price on Exact Sciences from $65.00 to $50.00 and set a "neutral" rating for the company in a research note on Wednesday, August 3rd. Robert W. Baird lowered their price objective on shares of Exact Sciences from $90.00 to $75.00 and set an "outperform" rating for the company in a research report on Wednesday, August 3rd. Evercore ISI upped their price objective on shares of Exact Sciences to $65.00 in a research report on Tuesday. Finally, The Goldman Sachs Group reduced their price target on Exact Sciences from $100.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday, April 19th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $71.00.

Exact Sciences Stock Down 6.4 %

Shares of EXAS Stock traded down $2.89 during trading on Thursday, reaching $42.24. The company's stock had a trading volume of 176,588 shares, compared to its average volume of 1,877,212. The company has a market cap of $7.47 billion, a price-to-earnings ratio of -10.67 and a beta of 1.32. Exact Sciences has a one year low of $35.34 and a one year high of $108.99. The business has a fifty day moving average price of $44.23 and a 200-day moving average price of $58.37. The company has a quick ratio of 2.23, a current ratio of 2.48 and a debt-to-equity ratio of 0.70.

Insider Activity

In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the firm's stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total value of $208,005.12. Following the transaction, the director now directly owns 60,318 shares of the company's stock, valued at approximately $2,722,754.52. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the business's stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the transaction, the director now owns 60,318 shares of the company's stock, valued at $2,722,754.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Katherine S. Zanotti sold 1,086 shares of the firm's stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $40.13, for a total transaction of $43,581.18. Following the completion of the sale, the director now owns 60,318 shares in the company, valued at $2,420,561.34. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,701 shares of company stock valued at $251,872. 1.30% of the stock is owned by insiders.

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Stock News Headlines

Exact Sciences (NASDAQ:EXAS) PT Raised to $65.00 at Evercore ISI
Exact Sciences (EXAS) Q2 2022 Earnings Call Transcript
Top 10 Stock Picks of Eli Casdin’s Casdin Capital
EXAS December 16th Options Begin Trading
See More Headlines
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Company Calendar

Last Earnings
11/01/2021
Today
8/11/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,500
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$71.00
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+67.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-595,630,000.00
Pretax Margin
-38.51%

Debt

Sales & Book Value

Annual Sales
$1.77 billion
Book Value
$18.14 per share

Miscellaneous

Free Float
174,660,000
Market Cap
$7.50 billion
Optionable
Optionable
Beta
1.32

Social Links















EXAS Stock - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXAS shares.
View EXAS analyst ratings
or view top-rated stocks.

What is Exact Sciences' stock price forecast for 2022?

11 analysts have issued 1-year price objectives for Exact Sciences' shares. Their EXAS share price forecasts range from $50.00 to $130.00. On average, they predict the company's share price to reach $71.00 in the next year. This suggests a possible upside of 65.3% from the stock's current price.
View analysts price targets for EXAS
or view top-rated stocks among Wall Street analysts.

How have EXAS shares performed in 2022?

Exact Sciences' stock was trading at $77.83 at the beginning of 2022. Since then, EXAS shares have decreased by 44.8% and is now trading at $42.95.
View the best growth stocks for 2022 here
.

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our EXAS earnings forecast
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings data on Monday, November, 1st. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.08. The medical research company had revenue of $456.38 million for the quarter, compared to analyst estimates of $429.04 million. Exact Sciences had a negative net margin of 37.90% and a negative trailing twelve-month return on equity of 22.07%. During the same period in the previous year, the company posted ($0.36) earnings per share.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.98 billion-$2.02 billion, compared to the consensus revenue estimate of $2.02 billion.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

141 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (8.51%), Sumitomo Mitsui Trust Holdings Inc. (3.30%), Nikko Asset Management Americas Inc. (3.02%), Baillie Gifford & Co. (2.49%), Swiss National Bank (0.43%) and Frontier Capital Management Co. LLC (0.30%). Insiders that own company stock include Canada Pension Plan Investment, D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Mark Stenhouse, Sarah Condella, Scott C Johnson and Torsten Hoof.
View institutional ownership trends
.

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $42.95.

How much money does Exact Sciences make?

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $7.60 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595,630,000.00 in net income (profit) each year or ($4.23) on an earnings per share basis.

How many employees does Exact Sciences have?

The company employs 6,500 workers across the globe.

Does Exact Sciences have any subsidiaries?

The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More

When was Exact Sciences founded?

Exact Sciences was founded in 1995.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.

This page (NASDAQ:EXAS) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.